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Hepatic lipase treatment of chylomicron remnants 
increases exposure of apolipoprotein E 
Dawn L. Brasaemle,' Kathleen Cornely-Moss,' and And& Bensadoun3 
Division of Nutritional Sciences and Division of Biological Sciences, Cornel1 University, Ithaca, NY 14853 
Abstract The consequences of hepatic lipase treatment of 
chylomicron remnants were studied. Rats were fed corn oil to in- 
duce production and secretion of chylomicrons and were then 
injected with polyclonal antiserum raised against hepatic lipase 
to specifically and quantitatively inhibit hepatic lipase activity in 
vivo. A fraction enriched in chylomicron remnants was isolated 
from rat plasma by a brief centrifugation step that preferentially 
isolates triglyceride-rich apolipoprotein (apo) B-48-containing 
lipoproteins. The chylomicron remnants were then treated with 
hepatic lipase in vitro, or incubated under identical conditions 
in the absence of enzyme (control incubations). Hepatic lipase- 
treated and control chylomicron remnants were isolated by a se- 
cond brief centrifugation step using discontinuous salt gra- 
dients. Control lipoproteins were collected from one discrete 
band at d < 1.02 g/ml. Hepatic lipase-treated chylomicron rem- 
nants formed two discrete bands and were collected at two densi- 
ties: d<1.02 g/ml and 1.02<d<1.04 g/ml. The buoyant 
(d < 1.02 g/ml) subfraction of hepatic lipase-treated chylomicron 
remnants was depleted of 62% of the total phospholipid when 
compared to control d < 1.02 g/ml lipoproteins. The dense 
(1.02 < d  <LO4 g/ml) subfraction of hepatic lipase-treated 
chylomicron remnants was depleted of 65% of particle phos- 
pholipid content and 90% of particle triglyceride content when 
compared to control d < 1.02 g/ml lipoproteins. The dense 
(1.02 < d  < 1.04 g/ml) subfraction of hepatic lipase-treated 
chylomicron remnants showed 5- to 7-fold greater immunoreac- 
tivity of apoE when compared to control lipoproteins in com- 
petitive displacement immunoassays. I These data suggest 
that extensive hydrolysis of chylomicron remnant phospholipid 
and triglyceride leads to the formation of a dense remnant parti- 
cle that contains highly exposed apoE. This increased exposure 
of apoE may be the key to the previously observed increased 
degradation of chylomicron remnants treated with hepatic lipase 
because more exposed apoE may bind better to cell surface 
lipoprotein receptors. Furthermore, the data imply that hepatic 
lipase cleaves chylomicron remnant phospholipid and triglycer- 
ide in a sequential fashion; hydrolytic intermediates depleted 
only of phospholipid precede the formation of a smaller dense 
remnant particle depleted of phospholipid and triglyceride. - 
Brasaemle, D. L., K. Cornely-Moss, and A. Bensadoun. 
Hepatic lipase treatment of chylomicron remnants increases ex- 
posure of apolipoprotein E. J.  Lipid Res. 1993. 34: 455-465. 
Supplementary key words lipolysis triglyceride hydrolysis phos- 
pholipid hydrolysis chylomicron remnant subfractions * immuno- 
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Dietary lipids are packaged into chylomicrons in intes- 
tinal epithelial cells. Nascent chylomicrons are large 
( > 1000 A)  triglyceride-rich lipoproteins containing 
apolipoprotein A-I (apoA-I), apoA-IV, and apoB-48 
(reviewed in refs. 1 and 2). Chylomicrons are secreted 
into the lymph and enter the general circulation after pas- 
sage through the thoracic duct. Circulating chylomicrons 
acquire apoC-I1 which acts as a co-factor for lipoprotein 
lipase. Lipoprotein lipase associated with endothelial cell 
surfaces of capillary beds hydrolyzes a large portion of 
triglyceride in the lipoprotein core. This lipolysis leads to 
remodeling of the lipoprotein characterized by loss of both 
core and excess surface components. The resulting 
chylomicron remnant acquires apoE from circulating 
lipoproteins. 
Chylomicron remnants are removed from the circula- 
tion primarily by the liver, and by bone marrow and 
spleen in some species (3, 4). Clearance of chylomicron 
remnants is mediated by interaction of apoE on the 
lipoprotein surface with specific cell surface receptors 
Hepatic lipase appears to play a role in the metabolism 
of triglyceride-rich lipoproteins. Several examples of 
heritable hepatic lipase deficiency in humans have been 
described (10-17). Common features among these subjects 
include elevated fasting serum triglyceride levels and the 
accumulation of triglyceride-enriched remnant particles 
isolated by centrifugation from the density ranges of inter- 
mediate density lipoproteins and low density lipoproteins. 
(5-9). 
Abbreviations: VLDL, very low density lipoprotein. 
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Additionally, hepatic lipase catalytic activity has been 
blocked by injection of specific polyclonal antisera into 
both fasted and lipid-fed experimental animals to yield 
similar accumulations of remnant particles in plasma 
(18-25). These observations suggest that hepatic lipase is 
necessary to clear triglyceride-rich lipoprotein remnants 
from the circulation. 
The probable mechanism of hepatic lipase-assisted 
metabolism of triglyceride-rich lipoproteins involves 
hydrolysis of lipids in the circulating lipoproteins by the 
enzyme. In vitro, hepatic lipase acts as a phospholipase 
and a hydrolase of neutral glycerides in a number of 
model systems including isolated lipoproteins (reviewed 
in refs. 26 and 27). Hepatic lipase is synthesized in 
hepatocytes and, after secretion, binds to endothelial cell 
surfaces in liver, adrenal gland, and ovary (reviewed in 
ref. 28). From these locations, it comes into contact with 
circulating lipoproteins; ensuing hydrolysis of phos- 
pholipids and triglycerides may increase the exposure of 
apolipoproteins essential for receptor-mediated uptake of 
the lipoproteins. 
The purpose of this study was to examine the conse- 
quences of hepatic lipase-catalyzed hydrolysis of 
chylomicron remnant lipids and to test the hypothesis that 
this activity of hepatic lipase increases the immunoreac- 
tivity of apoE on chylomicron remnants. We collected 
triglyceride-rich lipoproteins from corn oil-fed rats in- 
jected with polyclonal antibodies raised against hepatic li- 
pase to block enzyme activity. The collected lipoproteins 
were thus subjected to lipolysis by lipoprotein lipase in 
vivo, but not to hydrolysis by hepatic lipase. A portion of 
the collected lipoproteins was treated with hepatic lipase 
in vitro; the remaining lipoproteins were incubated under 
identical conditions in the absence of enzyme. The lipid 
and apolipoprotein contents of hepatic lipase-treated and 
untreated (control) lipoproteins were compared. Hepatic 
lipase-treated chylomicron remnants were found to con- 
tain more immunoreactive apoE relative to total apoE 
than untreated lipoproteins; hence, hepatic lipase treat- 
ment inc~ased the exposure of apoE on Chylomicron remnants. 
MATERIALS AND METHODS 
Preparation of antiserum against rat apoE and anti-rat 
apoE immunoglobulin preparation 
ApoE was purified from rat d < 1.04 g/ml lipoproteins 
following methods adapted from previously published 
procedures (29, 30). Antiserum to purified rat apoE was 
raised in a goat. Goat anti-rat apoE immunoglobulins 
were purified from antisera by affinity chromatography 
using an apoE-Sepharose@ 4B column prepared by 
coupling apoE to CNBr-activated Sepharose@ 4B (Phar- 
macia) following the manufacturer's procedures. 
ELISA conditions for the determination of total apoE 
concentration of lipoproteins 
ApoE concentrations of lipoproteins were determined 
by a sandwich ELISA using affinity-purified polyclonal 
antibodies raised against rat apoE for both the capturing 
antibody and the horseradish peroxidase-tagged (31) anti- 
body. A sample buffer of 0.5 M NaCl, 1% bovine serum 
albumin (BSA), 0.05% Tween 20, 10 mM sodium phos- 
phate, pH 7.4, was used for sample and standard dilu- 
tions, and horseradish peroxidase-antibody conjugate ad- 
dition. This assay gave a linear increase in absorbance at 
490 nm with increasing concentrations of highly purified 
apoE to 1 ng. The affinity-purified polyclonal antibody 
used in this assay showed no cross reactivity to apoB; 100 
ng of apoB-48 gave no detectable absorbance at 490 nm. 
To maximally expose epitopes of apoE on the surface of 
triglyceride-rich (d < 1.02 g/ml) lipoproteins, lipoprotein 
samples (and purified apoE standards) were incubated for 
1 h at 37OC in 10 mM sodium dodecyl sulfate (SDS) be- 
fore further dilution and addition to the assay plates. As 
SDS interferes with the detection of apoE, the final con- 
centrations of SDS in all diluted samples and standards 
were adjusted to be equal and less than or equal to 0.5 mM. 
ELISA conditions for the determination of exposed 
apoE on lipoprotein fractions 
Exposure of apoE on the surfaces of lipoproteins was 
assayed using a competitive displacement immunoassay. 
Alternate rows of 96-well ELISA plates were coated with 
purified rat apoE; alternate rows were coated with buffer 
containing no apoE, to serve as controls for nonspecific 
binding. Serial dilutions of lipoproteins were made in 3 % 
BSA, phosphate-buffered saline (PBS), pH 7.4. The goat 
anti-rat apoE immunoglobulin-horseradish peroxidase 
conjugate was diluted in 3% BSA, PBS, pH 7.4, and was 
added to the serial dilutions of lipoproteins. The 
lipoprotein solutions were incubated briefly on ice and 
then added to both apoE-coated and control (uncoated) 
wells of the ELISA plates. Soluble lipoprotein/antibody 
complexes were removed by washing, and an o-phenylene- 
diamine substrate solution was used to quantitate im- 
munoglobulin-horseradish peroxidase complexed with 
immobilized apoE. 
Data were expressed as the ratio of the absorbances at 
490 nm of sample wells (B) to the average absorbance at 
490 nm of wells incubated with dilute goat anti-rat apoE 
immunoglobulin-horseradish peroxidase conjugate 
without competing lipoprotein (Bo). The B/Bo ratio was 
then plotted as a function of the total apoE content of 
lipoprotein samples determined by ELISA of SDS-treated 
lipoproteins. Binding curves were analyzed simultane- 
ously using the ALLFIT program (1992 version deve- 
loped by DeLean, A., P. J. Munson, V. Guardabasso, and 
D. Rodbard, National Institutes of Health, Bethesda, 
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MD) on an IBM-PC; this program fits families of sigmoi- 
dal curves using the four-parameter logistic equation (32). 
Slopes of fitted curves and midpoint values of binding 
isotherms (EDs0) were determined. 
16,900 or 29,400 pmol fatty acid released per h, as deter- 
mined using a tri[3H]oleoylglycero1 substrate. 
Purification of rat hepatic lipase for lipolysis of 
lipoproteins in vitro 
Preparation of antiserum against rat apoB-100 and 
anti-rat apoB-48 immunoglobulin preparation 
ApoB-100 and apoB-48 were isolated from rat very low 
density lipoproteins (VLDL) using the procedures of Zil- 
versmit and Shea (33). Purified rat apoB-100 was used to 
immunize a goat. Goat anti-rat apoB-48 immunoglobulin 
was purified from antisera raised against apoB-100 using 
an apoB-48-Affi-gel 10 column prepared by coupling 
apoB-48 to Affi-gel 10 (Bio-Rad) following the manufac- 
turer’s instructions. 
ELISA conditions for the determination of total 
apoB-48 concentration of lipoproteins 
ApoB concentrations of lipoproteins were determined 
by a sandwich ELISA using affinity-purified 
apoB-48-specific polyclonal antibodies for both the cap- 
turing antibody and the horseradish peroxidase-tagged 
(31) antibody. A sample buffer of 1% BSA, 0.025% Tween 
20, PBS, pH 7.4, was used for sample and standard dilu- 
tions, and horseradish peroxidase-antibody conjugate ad- 
dition. This assay gave a linear increase in absorbance at 
490 nm with increasing concentrations of highly purified 
apoB-48 or apoB-100 to 20 ng; the slope of the standard 
curve .for apoB-100 was approximately 50% of the slope 
of the standard curve for apoB-48. The affinity-purified 
polyclonal antibody used in this assay showed no cross- 
reactivity to apoE; 100 ng of apoE gave no detectable ab- 
sorbance at 490 nm. 
To maximally expose epitopes of apoB on the surface of 
triglyceride-rich (d < 1.02 g/ml) lipoproteins, lipoprotein 
samples (and purified apoB-48 standards) were incubated 
for 1 h at 37OC in 5% Triton X-100 before further dilution 
and addition to the assay plates. Incubation of 
lipoproteins with 5% Triton X-100 was more effective at 
increasing exposure of epitopes on apoB than incubation 
of lipoproteins with 10 mM SDS, 1% Triton X-100, rat 
hepatic lipase, or bee venom phospholipase AP. Concen- 
trations of Triton X-100 ranging from 0.1% to 5% inter- 
fered minimally with the ability to quantitate apoB-48 by 
ELISA; nevertheless, the Triton X-100 concentrations of 
all samples and standards were adjusted to be equal and 
less than or equal to 0.1%. 
Hepatic lipase was purified from rat liver perfusate by 
new methods that eliminate low levels of contaminant 
apoE and apoB (Bensadoun, A., D. L. Brasaemle, J. Hsu, 
and L. B. Hughes, unpublished results). Briefly, perfusate 
was collected from 60 adult male rat livers and concen- 
trated using PM30 Diaflo Ultrafiltration Membranes 
(Amicon Corporation, Danvers, MA) in an Amicon con- 
centration cell at 4OC. All subsequent steps were carried 
out at 4OC. 
The concentrated liver perfusate was dialyzed against 
20 mM Tris, pH 7.2, and loaded onto a 1.5 cm x 11 cm 
Q-Sepharosem (Pharmacia) column equilibrated with 2.5 
mM n-decylsucrose (CALBIOCHEM), 20 mM Tris, pH 
7.2. The column was washed extensively with 20 mM 
Tris, pH 7.2, and 0.2% Triton X-100, 20 mM Tris, pH 
7.2. Bound hepatic lipase was eluted with a 400-ml gra- 
dient of 0-1.0 M NaCl in 2.5 mM n-decylsucrose, 20 mM 
Tris, pH 7.2. Column fractions containing enzyme ac- 
tivity were pooled, the buffer was adjusted to contain 20% 
glycerol, and the pooled fractions were loaded onto a 2.6 
cm x 31 cm heparin Sepharose@ (Pharmacia) column 
equilibrated with 20 mM Tris, pH 7.2. The column was 
washed extensively with 20% glycerol, 20 mM Tris, pH 
7.2, and 0.1% Triton N101, 20% glycerol, 20 mM Tris, 
pH 7.2. Bound hepatic lipase was eluted with a 400-ml 
gradient of 0-1.2 M NaCl in 2.5 mM n-decylsucrose, 20 
mM Tris, pH 7.2. Column fractions containing hepatic li- 
pase catalytic activity were pooled and dialyzed against 
2.5 mM n-decylsucrose, 20% glycerol, 10 mM sodium 
phosphate, pH 7.2 
Pooled and dialyzed fractions containing hepatic lipase 
activity were loaded onto a 1.6 cm x 7 cm S-Sepharose@ 
(Pharmacia) column equilibrated with 20% glycerol, 10 
mM sodium phosphate, pH 7.2. The column was washed 
extensively with the column equilibration buffer, and then 
eluted with a 300-ml gradient of 0-1.0 M NaCl in 2.5 mM 
n-decylsucrose, 20% glycerol, 10 mM sodium phosphate, 
pH 7.2. Hepatic lipase purified by these methods showed 
a major band at 55,000 daltons and a faint band at 59,000 
daltons in Coomassie blue R-250-stained SDS- 
polyacrylamide gels, and showed no contamination by 
apoE or apoB as determined by ELISA. The specific ac- 
_.  
Hepatic lipase was purified from rat liver perfusate and 
used to immunize a goat as described previously (34). 
The titers of two antisera used in these studies were deter- 
mined by the method described previously by Kompiang, 
Bensadoun, and Yang (35). One ml of antiserum in- 
hibited hepatic lipase activity at a level equivalent to 
taining hepatic lipase catalytic activity were pooled and 
concentrated for use in experiments by elution over a 
small (1 g) heparin Sepharose@ column equilibrated with 
0.1% BSA, 30% glycerol, 10 mM sodium phosphate, pH 
7.4. The column was washed with the column equilibra- 
tion buffer, and then eluted with 1% BSA, 1.0 M NaCl, 
Braramale, Comely-Moss, and Bensadoun Hepatic lipase treatment of chylomicron remnants 45 7 
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30% glycerol, 10 mM sodium phosphate, pH 7.4. Con- 
centrated hepatic lipase was stored at -8OOC before use. 
Collection of chylomicron remnants 
Male Long-Evans rats (Harlan Sprague-Dawley), 
270-370 g, were fed commercial rat chow ad libitum 
throughout the study. To increase absorbed lipid, rats 
were fed 2 ml of corn oil emulsified by sonication with 5 % 
sodium taurodeoxycholate in a 1:l (dv) ratio by gastric in- 
tubation. Immediately after corn oil gavage, each rat was 
anesthetized with ether, and injected via the jugular vein 
with 1 ml goat antiserum raised against rat hepatic lipase. 
The antiserum used in this study had a titer 7- to 13-fold 
higher than that previously demonstrated to specifically 
and completely inhibit the activity of heparin-releasable 
hepatic lipase when injected into rats (22). After 3 h, the 
rats were injected with an additional 1 ml goat anti-rat 
hepatic lipase serum via the jugular vein. Six h after the 
corn oil gavage and initial injection of antiserum, the 
animals were exsanguinated by cardiac puncture. 
Triglyceride-rich, apoB-48-containing lipoproteins 
were isolated from plasma by centrifugation. The density 
of the collected plasma was adjusted to d = 1.04 g/ml with 
a salt solution containing NaCl and NaBr; centrifuge 
tubes containing this plasma were overlaid with d 1.02 
g/ml salt solution and centrifuged for 25 min at 202,000 
g (average) in a Beckman SW 40 rotor at 14OC. 
Lipoproteins of d < 1.02 g/ml were collected by slicing the 
tubes and were stored at 4OC overnight. 
Treatment of triglyceride-rich lipoproteins with 
purified rat hepatic lipase in vitro and further 
isolation of remnant lipoproteins 
Triglyceride-rich d < 1.02 g/ml lipoproteins were treated 
with purified rat hepatic lipase in vitro for 1 h at 35°C. 
Hepatic lipase was added to the lipoprotein solutions at a 
level of 19-39 units of enzyme activity (pequivalents fatty 
acid released from triglyceride per h) per mg lipoprotein 
triglyceride. The incubation mixture contained 
lipoprotein and hepatic lipase in 10 mg/ml BSA, 0.5 M 
NaCl, 10 mM CaC12, 0.2 M Tris, pH 8.6. A control incu- 
bation contained all components except hepatic lipase. 
Control and hepatic lipase-treated remnants were iso- 
lated by ultracentrifugation using discontinuous salt gra- 
dients. The density of each incubation mixture was ad- 
justed to 1.08 g/ml with a salt solution containing NaCl 
and NaBr, and the lipoprotein solutions were overlaid 
with d 1.04 g/ml, and then d 1.02 g/ml salt solutions. The 
gradients were centrifuged for 75 min at 202,000 g in a 
Beckman SW40 rotor at 14°C. Lipoproteins were har- 
vested by slicing the tubes. 
Analysis of chylomicron remnant composition 
The compositions of control and hepatic lipase-treated 
chylomicron remnants were determined. Apolipoprotein 
concentrations were determined by ELISAs within 8 h of' 
lipoprotein isolation. Total phospholipid content was cal- 
culated from the total phosphorus content (36) of solvent 
lipid extracts (37). Total and partial glyceride analysis was 
conducted by thin-layer chromatography of lipid extracts 
(37) followed by quantitation of glycerol content (38) of 
mono-, di-, and triglyceride extracts from thin-layer chro- 
matography silica gel scrapings. Total cholesterol content 
(cholesterol and cholesteryl esters) was determined using 
an enzymatic cholesterol assay kit from Boehringer- 
Mannheim (Kit ffl236691). Total protein content was de- 
termined by the method of Lowry et al. (39), using a BSA 
standard. SDS-PAGE of lipoprotein fractions and purified 
apolipoproteins was conducted using the methods of 
Laemmli (40). Statistical significance of composition 
differences between control and hepatic lipase-treated 
chylomicron remnants were evaluated by Student's paired 
t-test. 
RESULTS 
Isolation of apoB-48-containing lipoproteins from 
corn oil-fed rats 
Triglyceride-rich lipoproteins were collected from corn 
oil-fed rats with functionally inactive hepatic lipase. 
These lipoproteins were, however, exposed to lipoprotein 
lipase in vivo. The conditions used to collect triglyceride- 
rich lipoproteins from corn oil-fed rats were designed to 
maximize the recovery of apoB-48-containing lipoproteins 
with minimal contamination of the preparation with 
apoB-100-containing lipoproteins and minimal loss of 
apoE. When very brief centrifugations of 25 min with a 
SW40 rotor were used, d < 1.02 g/ml lipoprotein fractions 
were highly enriched in apoB-48 (see Fig. 1, lane 2). 
Levels of apoB-100 determined by densitometric scanning 
of Coomassie Blue R-250-stained SDS-PAGE gels (33) 
typically totaled less than 5% of the levels of apoB-48 
(data not shown). Previous studies have documented the 
secretion of apoB-48-containing lipoproteins by rat liver 
as well as intestine (41-45). Although we cannot rule out 
the presence of lipoproteins originating from liver in the 
collected d<1.02 g/ml fraction, the feeding of a bolus of 
corn oil to the rats should ensure an abundant supply of 
intestinally derived chylomicron remnants in circulation. 
Changes in chylomicron remnant density profiles after 
hepatic lipase treatment 
ApoB-48-containing d < 1.02 g/ml lipoproteins were 
treated with hepatic lipase in vitro. The lipolysis reaction 
was followed by isolation of the remnant products by 
ultracentrifugation of salt gradients. Lipoproteins from 
control incubations (no hepatic lipase) were collected in 
the same density range (d<1.02 g/ml) as the original 
triglyceride-rich lipoprotein. In four experiments, 
458 Journal of Lipid Research Volume 34, 1993 
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Fig. , l .  Coomassie Blue R25O-stained SDS-PAGE gel of lipoprotein 
fractions from density gradients. Lane 1 contains molecular mass stan- 
dards myosin (205 kD), @-galactosidase (116 kD), phosphorylase B (97.4 
kD), bovine serum albumin (66 kD), egg albumin (45 kD), and carbonic 
anhydrase (29 kD). Lane 2 contains d < 1.02 g/ml lipoproteins from the 
initial isolation of chylomicron remnants from plasma. Lanes 3-5 con- 
tain lipoproteins from various density fractions obtained from the cen- 
trifugal isolation of chylomicron remnants after hepatic lipase treatment. 
Lane 3 contains d < 1.02 glml control lipoproteins from incubations in 
the absence of hepatic lipase. Lane 4 contains 1.04 <d  < 1.02 g/ml dense 
remnants from hepatic lipase incubations. Lane 5 contains d < 1.02 g/ml 
lipoproteins from hepatic lipase incubations. Lanes 2-5 contain equal 
amounts of total protein. 
92-9876 of the apoB-48 recovered from control incuba- 
tion gradients was collected in this density range (Table 
1). The 1.02<d<1.04 g/ml fraction of the control 
lipoprotein gradients showed a very low concentration of 
apoB-48. Comparison of the protein composition of 
d < 1.02 g/ml lipoproteins from the control incubation 
(Fig. 1, lane 3) to that of the original d<1.02 g/ml 
lipoproteins (Fig. 1, lane 2) indicated a decrease in albu- 
min content and an enrichment of the relative 
apolipoprotein content of the lipoprotein fraction follow- 
ing the second centrifugation. 
Dense chylomicron remnants were formed during the 
treatment of triglyceride-rich lipoproteins with hepatic li- 
pase. The majority of chylomicron remnants from hepatic 
lipase incubations were collected from two density ranges 
of the salt gradients: d<1.02 g/ml and 1.02<d<1.04 
g/ml. In four experiments, 56-7376 of the apoB-48 reco- 
vered from the hepatic lipase treatment gradients was col- 
lected from the d < 1.02 g/ml density range, 21-3276 from 
the 1.02<d<1.04 g/ml range, and 4-1276 from the 
d>1.04 g/ml range (Table 1). Comparison of the protein 
composition of the hepatic lipase treatment d < 1.02 g/ml 
fraction (Fig. 1, lane 5) to the control d<1.02 g/ml frac- 
tion (Fig. 1, lane 3) showed similar apolipoprotein con- 
tent. The protein composition of the 1.02 <d  < 1.04 g/ml 
fraction, “dense remnants,” (Fig. 1, lane 4) indicates an en- 
richment of albumin relative to apolipoproteins. The in- 
creased albumin in the dense remnant fraction originated 
from BSA added to the lipolysis mixture. The addition of 
albumin during lipolysis is necessary to remove monoa- 
cylglycerides, lysophosphatidylcholine, and free fatty acid 
from the hydrolyzed lipoproteins (46, 47). Enrichment of 
albumin in the dense remnant fraction may result from 
increased affinity of the dense chylomicron remnants for 
albumin or from decreased washing effects for lipoprotein 
collected lower in the gradient. As the various lipoprotein 
fractions contained a variable content of contaminating 
albumin, comparisons of lipid content of these fractions 
were made on a per particle basis using apoB-48 content 
as an indicator of particle number. 
TABLE 1. Recovery of apolipoproteins E and B-48 in salt density gradient fractions 
Lipoprotein Density Fractions 
d 2 1.04 g/ml Sample d< 1.02 g/ml 1.02<d<1.04 g/ml 
% ofapoE recovered 
Control 66 f 11 
Hepatic lipase-treated 56 f 3’ 
Control 95 f 3 
Hepatic lipase-treated 66 f 7d 
2“ 
31 f 5 
% of apoB-48 recovered 
1” 
26 f 5 
32 f 10 
14 f 5‘ 
4 f 4  
8 f 4‘ 
Data are means f standard deviations for the average of duplicate ELISA analyses from four experiments. 
“Average of determinations from two experiments. 
*Differences between apoE recovery data of control d < 1.02 g/ml fractions and hepatic lipase-treated d < 1.02 
‘APE recovery data: control d 2  1.04 g/ml fractions vs. hepatic lipase-treated d r 1 . 0 4  g/ml fractions; P < 0.05. 
dApoB-48 recovery data: control d < 1.02 g/ml fractions vs. hepatic lipase-treated d < 1.02 g/ml fractions; 
' ApoB-48 recovery data; control d 2 1.04 g/ml fractions vs. hepatic lipase-treated d r  1.04 g/ml fractions; 
g/ml fractions are significant at a level of P < 0.10 by Student’s paired I-test. 
P < 0.005. 
P < 0.005. 
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Changes in chylomicron remnant lipid composition 
after hepatic lipase treatment 
Hepatic lipase hydrolyzes both surface phospholipid 
and core triglyceride of chylomicron remnants. Hepatic 
lipase-treated chylomicron remnants isolated at d < 1.02 
g/ml showed depletion of 62% of total phospholipid rela- 
tive to apoB-48 content when compared to control 
(d < 1.02 g/ml) lipoproteins; triglyceride content of this 
fraction was similar to control lipoproteins (Table 2). 
Dense hepatic lipase-treated remnants (1.02 < d < 1.04 
g/ml) showed depletion of 65% of total phospholipid and 
90% of triglyceride when compared to control (d < 1.02 
g/ml) lipoproteins. Therefore, the shift of a portion of 
hepatic lipase-treated chylomicron remnants to the higher 
density range between 1.02 g/ml and 1.04 g/ml was due to 
the large decrease in particle triglyceride content in addi- 
tion to depletion of phospholipid. Additionally, dense 
hepatic lipase-treated chylomicron remnants showed an 
increase in monoglyceride content relative to control 
lipoproteins. No significant differences in total cholesterol 
content per particle were observed. 
Measurements of lipid composition relative to apoB 
showed large variability between experiments. A potential 
source of variability was a wide range of particle size of 
the initial d < 1.02 g/ml lipoprotein. Triglyceride content 
of control lipoproteins covered a range of 80 to 180 pg 
triglyceridelpg apoB-48; thus, the starting chylomicron 
remnant core size varied considerably. The degree of 
hepatic lipase-catalyzed triglyceride hydrolysis of the 
starting d < 1.02 g/ml lipoprotein fraction also varied be- 
tween experiments. For four experiments, 21-32% of total 
apoB-48 (hence, 21-32% of the particles) was recovered in 
the dense remnant (1.02 < d  <LO4 g/ml) subfraction of 
hepatic lipase-treated lipoprotein; the triglyceride content 
of this dense subfraction varied from 6 to 23 pg triglycer- 
idelpg apoB-48. Despite experimental variability in lipid 
composition measurements, the pattern for these 
parameters was the same and significant differences were 
observed for all four experiments. 
Changes in apoE exposure and content with hepatic 
lipase treatment of chylomicron remnants 
The exposure of apoE on chylomicron remnants was 
studied using polyclonal antibodies raised against rat 
apoE in competitive displacement immunoassays. Im- 
munoreactivity of apoE on the hepatic lipase-treated 
dense subfraction of chylomicron remnants (1.02 < d < 
1.04 g/ml) was greater than that of control (d < 1.02 g/ml) 
lipoproteins (Fig. 2 and Table 3). The midpoints of the 
binding isotherms (EDSOs) were used to compare the rela- 
tive exposure of apoE in the two chylomicron remnant 
subfractions (Table 3); apoE on hepatic lipase-treated 
dense remnants (1.02 < d < 1.04 g/ml) was 5 -  to 7-fold 
more immunoreactive than apoE on control lipoproteins. 
Additionally, the slopes of binding isotherms from hepatic 
lipase-treated dense remnants (1.02 < d < 1.04 g/ml) were 
steeper than the slopes of the control (d<1.02 g/ml) 
lipoprotein binding curves (Table 3), implying increased 
binding affinity of polyclonal antibodies for apoE on 
hepatic lipase-treated chylomicron remnants. These data 
suggest that hepatic lipase treatment increases the num- 
ber of exposed epitopes on apoE for polyclonal antibody 
binding and that the consequent increased binding occurs 
with higher affinity. 
Similar competitive displacement immunoassays were 
used to compare the relative exposure of apoE on d < 1.02 
g/ml hepatic lipase-treated chylomicron remnants to con- 
trol (d < 1.02 g/ml) lipoproteins. In three experiments, the 
ratios of EDS0 values of binding isotherms of control over 
hepatic lipase-treated d < 1.02 g/ml lipoproteins were 0.9, 
3.6, and 3.0. Student's paired t-test analysis of EDs0 values 
and slopes indicated that differences between the two 
TABLE 2. Lipoprotein lipid composition 
Hepatic 
Lipase Hepatic Lipase 
Control Treatment Treatment 
d < 1 . 0 2  g/ml d < 1.02 g/ml Dense Remnants 
Lipid Component Fraction Fraction 1.02<d<1.04 g/ml 
,ug lipid/pg apoB-48 
Triglyceride 129 i 40 115 * 26 13.1 k 7.2"b 
9.72 i 5.12 5.09 i 1.84 Diglyceride 13.0 i 6.3 
Monoglyceride 4.28 f 2.94 8.65 f 5.26 7.12 f 4.81' 
5.90 + 2.14 Total cholesterol 5.81 i 1.85 5.99 i 1.61 
6.56 k 3.64' Phospholipid 18.78 i 4.73 7.10 i 2.40d 
Data are the means + standard deviation for duplicate lipid analyses of four separate experiments. 
"Differences between control d <  1.02 g/ml fractions and hepatic lipase treatment dense remnants (1.02 < d <  1.04 
'Hepatic lipase treatment d<1.02 g/ml fractions vs. hepatic lipase treatment dense remnants; P < 0.01. 
'Control d <  1.02 g/ml fractions vs. hepatic lipase treatment dense remnants; P < 0.05. 
dControl d <  1.02 g/ml fractions vs. hepatic lipase treatment d <  1.02 glml fractions; P <0.05. 
g/ml) are significant at a level OF P < 0.01 by Student's paired t-test. 
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Fig. 2. Competition by control (closed symbols) and hepatic lipase- 
treated (open symbols) chylomicron remnants with immobilized apoE 
for binding to soluble polyclonal goat anti-rat hepatic lipase IgG con- 
jugated to horseradish peroxidase. Lipoprotein concentration is ex- 
pressed as total apoE mass determined by ELISA of SDS-treated 
lipoproteins. B/Bo values represent absorbance of ELISA sample wells 
containing lipoprotein/absorbance of wells containing only immobilized 
apoE. Data shown are averages of duplicate values from one representa- 
tive experiment out of four. 
lipoprotein fractions were not statistically significant 
(P = 0.19); hence, it is unclear whether the hydrolysis of 
phospholipids observed in hepatic lipase-treated d < 1.02 
g/ml lipoproteins leads to increased exposure of apoE. 
ApoE recovery data from lipoprotein fractions isolated 
by density gradients suggest that a portion of apoE is 
loosely associated with chylomicron remnants. Approxi- 
mately 30% of apoE was isolated in d 2 1.04 g/ml fractions 
of control lipoproteins (Table 1); apoB content of the same 
fractions was very low (4% of recovered apoB). These 
data imply that apoE recovered from d 5 1.04 g/ml frac- 
tions of control samples is not associated with 
lipoproteins. In agreement with our findings, other 
researchers have observed the dissociation of apoE from 
lipoproteins during centrifugation (48, 49). Less apoE 
was recovered in d 11.04 g/ml fractions from density gra- 
dients of hepatic lipase-treated lipoproteins than from the 
same fractions of control lipoproteins; greater apoB con- 
tent was measured in these dense fractions from hepatic 
lipase-treated lipoproteins (compared to control 
lipoproteins). These data suggest that at least some of the 
apoE was associated with lipoproteins in the d 2 1.04 g/ml 
fractions of hepatic lipase-treated chylomicron remnants. 
Additional apoE and apoB were found at an intermediate 
density (1.02 < d < 1.04 g/ml) in the dense chylomicron 
remnants fraction of hepatic lipase-treated lipoproteins. 
Competitive displacement immunoassays were used to 
determine whether apoE on the original d<1.02 g/ml 
chylomicron remnants isolated after a single centrifuga- 
tion step was more immunoreactive than apoE remaining 
on control d < 1.02 g/ml lipoproteins after the second cen- 
trifugation step. Immunoreactivity of apoE on control 
d < 1.02 g/ml chylomicron remnants after a second cen- 
trifugation was equal to that of the original d < 1.02 g/ml 
lipoproteins (Fig. 3). This observation demonstrates that 
loss of 30% of the total apoE from the initial chylomicron 
remnant does not change the immunoreactivity of the re- 
maining apoE. 
Hepatic lipase-treated chylomicron remnants collected 
at d < 1.02 g/ml and 1.02 < d  < 1.04 g/ml showed an enrich- 
ment of apoE relative to apoB when compared to d < 1.02 
g/ml lipoproteins from control (untreated) incubations 
(Table 4). This observation coupled with the lower con- 
tent of free apoE in high density fractions (d 2 1.04 g/ml) 
of hepatic lipase-treated lipoproteins (Table l), suggest 
that chylomicron remnants exposed to hepatic lipase con- 
tain more tightly associated apoE than the untreated con- 
trol lipoproteins. 
TABLE 3. Effect of heoatic lipase treatment on immunoreactivity of apoE on chylomicron remnants 
Hepatic Lipase EDSo Controll 
Control Treatment ED,, Hepatic 
Fraction (1.0'2 < d C 1.04 g/ml) Treatment 
Experiment # ED50 Slope EDw Slope Remnants 
Dense Remnants Lipase 
Dense 
dc1.02 g/ml 
1 5.27 0.282 1.10 0.565 4.79 
2 16.84 0.366 2.42 0.612 6.96 
3 21.83 0.316 3.08 0.541 7.09 
4 15.23 0.366 3.04 0.473 5.01 
Mean 14.79 0.332 2.41 0.548 5.96 
* SD f 6.94 0.041 f 0.92" + 0.058" f 1.23 
Competitive binding isotherm midpoint (ED,,) values and slopes were determined using the ALLFIT program 
"Differences between control d < 1.02 g/ml fraction and hepatic lipase treatment dense remnants are significant 
as described in Materials and Methods. 
at a level of P < 0.05 by Student's paired t-test. 
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of chylomicron remnants formed in vitro following exten- 
sive phospholipid and triglyceride hydrolysis. 
The isolation of chylomicron remnants extensively 
hydrolyzed by hepatic lipase in vivo has proven difficult to 
accomplish. Chylomicrons are cleared very rapidly from 
circulation (t112 = approximately 10 min) in rats (50). 
Furthermore, difficulty in obtaining chylomicron rem- 
nants exposed to hepatic lipase in vivo may be related to 
liver morphology and location of hepatic lipase in the 
liver. Triglyceride-rich lipoproteins that are small enough 
to pass through the fenestrae of liver endothelial cells be- 
come sequestered in the Space of Disse before interaction 
with cell surface receptors on hepatocytes. Recent studies 
have found a concentration of hepatic lipase in the Space 
of Disse (E. J. Blanchette-Mackie and R. 0. Scow, per- 
sonal communication) where it may be bound to heparan 
sulfate proteoglycans (28) and come into contact with se- 
Fig. 3. Competition by d<1.02 g/ml lipoprotein isolated after one cen- questered lipoproteins, Within the Space of Disse, 
trifugation step (closed symbols) and control d <  1.02 g/ml lipoprotein 
isolated after mock hepatic lipase incubation and a second centrifugation lipoproteins may be acted upon by hepatic lipase, bind 
step (open symbols) with immobilized apoE for binding to soluble poly- cell surface receptors, and then be rapidly internalized. 
clonal goat anti-rat hepatic lipase IgG conjugated to horseradish peroxi- Increases in chylomicron remnant apoE exposure after 
dase. Lipoprotein concentration is expressed as total apoE mass deter- hydrolysis of remnant lipids by hepatic lipase may be the mined by ELISA of SDS-treated lipoproteins. BlBo values represent 
key to increased binding of chylomicron rfx"nts to cell 
wells containing only immobilized apoE. Data shown are averages of surface ]ipoprotein receptors, Previous studies have 
duplicate values. shown that rat lymph chylomicrons treated with hepatic 
absorbance of ELISA sample wells containing lipoprotein/absorbance of 
DISCUSSION 
The major findings of this study are that 1) hydrolysis 
of lipids by hepatic lipase leads to increased immunoreac- 
tivity of apoE on chylomicron remnants, and 2) hepatic 
lipase hydrolyzes chylomicron remnant phospholipid and 
triglyceride in a stepwise fashion in vitro. Evidence sup- 
porting sequential hydrolysis of phospholipid and 
triglyceride was obtained from the isolation of a hydrolytic 
intermediate depleted only of phospholipid, in addition to 
a small remnant particle extensively depleted of phos- 
pholipid and triglyceride. Significant increases in apoE 
immunoreactivity were observed in this dense subfraction 
lipase are taken up more readily by liver than native 
chylomicrons or chylomicron remnants treated solely with 
lipoprotein lipase (51). Uptake of chylomicron remnants 
by the liver is mediated by apoE binding to cell surface 
receptors (5-9). Our data demonstrate that hepatic lipase 
hydrolytic activity increases the immunoreactivity of 
apoE, and may thereby enhance chylomicron remnant 
clearance. The increased exposure of apoE may be essen- 
tial for binding of the lipoprotein to cell surface receptors. 
Further experimentation is necessary to test this hypothesis. 
The chylomicron remnants used in our studies were the 
product of lipolysis by lipoprotein lipase in vivo and 
hepatic lipase in vitro. Previous studies have shown that 
depletion of core and surface lipids by hydrolysis of 
VLDL with bovine milk lipase increased immunoreac- 
tivity of apoB (52, 53); however, no change in im- 
TABLE 4. Apolipoprotein E/apolipoprotein B molar ratios for lipoprotein fractions 
Hepatic Lipase 
Hepatic Lipase Treatment 
Control Treatment Dense Remnants 
d<1.02 g / d  d < 1.02 g/ml (1.02 <g< 1.04 
Experiment # Fraction Fraction d m l )  
2 
3 
4 
Mean & SD 
1.44 
1.32 
1.58 
1.50 
1.46 rf. 0.11 
1.83 
2.04 
1.93 
1.54 
1.84 & 0.21" 
2.41 
1.55 
4.25 
2.60 
2.70 i 1.13h 
"Differences between control d <  1.02 g/ml fractions and hepatic lipase treatment d C 1.02 g/ml fractions are sig- 
'Control d<1.02 g/ml fractions vs. hepatic lipase treatment dense remnants; P = 0.094. 
nificant at a level of P = 0.074 by Student's paired t-test. 
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munoreactivity was observed when two different poly- 
clonal antibody preparations were used to probe relative 
apoE exposure (52). Although immunoreactivity of apoE 
varies among lipoprotein populations (54, 55), no clear 
correlations between apoE exposure and lipoprotein size 
or lipid composition have previously been made. Our 
studies begin to characterize the contribution that hepatic 
lipase makes to apoE exposure, but do not address the 
relative contribution of lipoprotein lipase. It is possible 
that lipoprotein lipase can create a similar dense remnant 
particle during extended circulation of chylomicron rem- 
nants. Alternatively, lipoprotein lipase may initiate the 
lipolysis of chylomicrons, thus facilitating entry of 
lipoproteins into the Space of Disse in the liver and allow- 
ing subsequent lipolysis by hepatic lipase. 
Possible mechanisms for the increased exposure of 
apoE after hepatic lipase treatment of chylomicron rem- 
nants include hydrolysis of surface lipids covering regions 
of apoE, and conformational changes of apoE resulting 
from hydrolysis of the lipoprotein core lipid. Data ob- 
tained in this study indicate that large increases in ex- 
posure of apoE result only after considerable hydrolysis of 
both surface phospholipid and core triglyceride; hence, 
extensive remodelling of the lipoprotein structure is re- 
quired for the observed increased immunoreactivity de- 
tected using polyclonal antibodies raised against apoE. 
Several studies have demonstrated that depletion of 
chylomicron remnant phospholipid content greatly in- 
creases the rate of chylomicron uptake by perfused liver 
(56, 57). Our studies suggest that triglyceride hydrolysis 
in addition to phospholipid hydrolysis is necessary for in- 
creased exposure of apoE. It is possible that hepatic 
lipase-catalyzed phospholipid hydrolysis increases ex- 
posure of essential receptor-binding regions of apoE to an 
extent that is below the sensitivity of our assay. Alterna- 
tively, surface phospholipid hydrolysis may expose under- 
lying core triglycerides for further hydrolysis by hepatic li- 
pase. Additional experimentation is necessary to resolve 
the relative contributions of hepatic lipase-catalyzed phos- 
pholipid and triglyceride hydrolysis to increased binding 
of chylomicron remnants to cell surface receptors. 
Chylomicron remnants depleted of phospholipid and 
triglyceride content by hepatic lipase treatment had a 
higher content of apoE per particle than control (un- 
treated) chylomicron remnants. The relative increase in 
apoE appeared to be due to decreased stripping of apoE 
from the lipid-depleted particles during centrifugation 
used to isolate the remnants. These observations suggest 
that chylomicron remnants depleted of phospholipid or 
phospholipid and triglyceride contain more tightly as- 
sociated apoE than lipid-rich remnants. Current studies 
are probing the binding of exogenous free apoE to 
chylomicron remnants generated by hepatic lipase treat- 
ment in vitro to determine whether these lipoproteins 
have an enhanced affinity for apoE. #I 
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